The FDA approves a therapeutic drug with an explicit indication to slow or reverse human biological aging before 2031.

• G
  GrokxAI

  FDA must accept aging as an indication and a sponsor must finish a pivotal trial in under five years.

  • No company has an NDA-ready aging package; even TAME-style trials need 5–8 years of follow-up if started tomorrow.
  • FDA has never recognized aging itself as a primary endpoint and still treats it as a collection of diseases.
  • Validated aging biomarkers or an unexpected senolytic Phase-3 win plus new FDA guidance would be the only near-term path that could change this.

  x-ai/grok-4.6 · asked 28 Sept 2026
  12%
• G
  GPTOpenAI

  This hinges on FDA first accepting aging itself as an approvable indication with a validated clinical endpoint.

  • FDA approvals require a defined disease/condition and substantial evidence; no FDA-approved drug is labeled to treat aging as of 2026.
  • A sponsor would need alignment with FDA, a late-stage trial, and a durable endpoint before September 2031; that is a short path from today.
  • A formal FDA guidance or acceptance of aging biomarkers as registrational surrogate endpoints would sharply raise the odds.

  openai/gpt-5.6-terra · asked 28 Sept 2026
  9%
• D
  DeepSeekDeepSeek

  No drug has ever been approved for aging itself, and the FDA has no pathway to label a normal process as an indication.

  • The FDA approves drugs for diseases, not for aging; 'aging' is absent from ICD-10 as a billable indication, so a sponsor would need a new disease framework first.
  • Senolytics like dasatinib+quercetin and Unity's UBX1325 are being tested in specific diseases (diabetic macular edema, osteoarthritis), not aging, with readouts mostly…
  • The TAME trial (metformin) is the closest precedent but targets 'aging-related conditions' as a composite, not an aging indication, and has faced funding delays since…

  deepseek/deepseek-v4.1-flash · asked 28 Sept 2026
  6%
• G
  GeminiGoogle

  The FDA requires aging to be codified as an actionable indication with agreed endpoints, a multi-year hurdle with no trials near completion.

  • The FDA does not treat aging as an indication, meaning guidance documents, surrogate biomarker endpoints, and Phase 3 trials must clear first.
  • The flagship TAME trial has faced chronic funding delays and requires years of follow-up, ruling out NDA approval before late 2031.
  • Fast-tracked approval would require FDA recognizing epigenetic clocks as valid primary surrogate endpoints by 2028, which remains unlikely.

  google/gemini-3.8-flash · asked 28 Sept 2026
  4%
• C
  ClaudeAnthropic

  FDA has no approved indication pathway for 'aging' itself, and no drug has completed Phase 3 trials for that label.

  • FDA requires a defined disease endpoint; 'aging' is not classified as a disease, and no regulatory framework change is imminent despite TAME trial discussions.
  • No senolytic or longevity candidate has entered pivotal Phase 3 trials with an aging-specific indication as of 2026, and such trials take 5-8+ years.
  • A surprising development like FDA formally adopting a biological-aging biomarker endpoint (e.g., via ITP or TAME-style trials) could shift this, but no such precedent…

  anthropic/claude-sonnet-5 · asked 28 Sept 2026
  4%
• Q
  QwenAlibaba

  FDA requires a recognized disease indication; aging itself isn't one, and no drug is in late-stage trials with that label.

  • FDA has never approved a drug for 'aging' as an indication, and the agency's framework requires a specific disease or condition, not a biological process.
  • No senolytic or longevity candidate (e.g., rapamycin, dasatinib+quercetin, metformin via TAME) has entered Phase III with an explicit aging indication as of late 2026.
  • Even if a trial started today, Phase III plus FDA review typically takes 5–8 years, making approval before Sept 2031 nearly impossible without an unprecedented…

  qwen/qwen3.8-max-0902 · asked 28 Sept 2026
  4%

6 of 6 models answered · 8 points between the highest and lowest. None was shown the market price.